|Health Discovery Corporation Responds to "Tabloid News" Report|
|Monday, 22 February 2010 08:19|
Health Discovery Corporation (OTCBB: HDVY) has responded to what it calls a "tabloid story" from TheStreet.Com's Adam Feuerstein that appeared on the internet last Friday and contained a number of "untruths."According to the company, it is worth noting that it appears that Health Discovery Corporation is caught in ongoing crossfire between two competing stock market news services, one that recently issued an independent, positive report on the Company (BioMedReports) that was, in turn, followed by the tabloid story (TheStreet.com) last week.
HDVY joins a growing list of publicly traded companies and CEOs who have complained about Feuerstein's lack of journalistic accuracies and reckless disregard for scientific data. It seems retail investors are the ones who most often complain and suffer financial loses due to the "misleading bash reports" which are penned time and again by Feuerstein and TheStreet.com.
The Company points out the following in an official news release this morning:
Here are some independent commentaries on the PSA:
Dr. Otis Brawley, the chief medical officer of the
The New England Journal of Medicine published in March 2009 the results of the largest prostate cancer studies in the U.S. and Europe, which said: “We now know that prostate-cancer screening (PSA) provided no reduction in the death rates at 7 years and that no indication of a benefit appeared with 67% of the subjects having completed 10 years of follow-up.”
“The rate of overdiagnosis of prostate cancer has been estimated to be as high as 50% in the (PSA) screening group… Overdiagnosis and overtreatment are probably the most important adverse effects of prostate-cancer screening and are vastly more common than in screening for breast, colorectal, or cervical cancer.”
New York Times reporter, Tara Parker Pope, wrote about these two major studies on prostate cancer and the merits of the PSA: “…[the PSA] saves few if any lives, while exposing patients to aggressive and unnecessary treatments that can leave them impotent and incontinent.”
Wall Street Journal writer Melinda Beck wrote about these two studies: “But two big studies in the New England Journal of Medicine just found that screening for PSA - prostate specific antigen - doesn't save many lives.”
Dr. Bernadine Healy, former head of the
According to oncologist Jonathan Simons, president of the Prostate Cancer Foundation, “We’ve got potentially game-changing biomarkers that could get us out of the dilemma we are in with the PSA.”
Health Discovery Corporation agrees with the outcomes of the two largest, published studies on the PSA and prostate cancer that there is an urgent need to replace the PSA and with Dr. Brawley’s assessment of the serious risks that the PSA test will ruin your life, with Dr. Healy’s observation about unnecessary expense and treatment, and with Dr. Simons’ keen observation about the value of new game-changing biomarkers.